Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial.

MLA

Margolis, Karen L., et al. “Development of a Standardized Definition for Clinically Significant Bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) Trial.” Contemporary Clinical Trials Communications, vol. 11, May 2018, pp. 30–36. EBSCOhost, https://doi.org/10.1016/j.conctc.2018.05.015.

APA

Margolis, K. L., Mahady, S. E., Nelson, M. R., Ives, D. G., Satterfield, S., Britt, C., Ekram, S., Lockery, J., Schwartz, E. C., Woods, R. L., McNeil, J. J., & Wood, E. M. (2018). Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Contemporary Clinical Trials Communications, 11, 30–36. https://doi.org/10.1016/j.conctc.2018.05.015

Chicago

Margolis, Karen L, Suzanne E Mahady, Mark R Nelson, Diane G Ives, Suzanne Satterfield, Carlene Britt, Saifuddin Ekram, et al. 2018. “Development of a Standardized Definition for Clinically Significant Bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) Trial.” Contemporary Clinical Trials Communications 11 (May): 30–36. doi:10.1016/j.conctc.2018.05.015.